This brand name is authorized in Singapore
The drug CANDID-B contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Clotrimazole
UNII G07GZ97H65 - CLOTRIMAZOLE
|
|
Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc. |
|
2
Beclometasone
UNII 5B307S63B2 - BECLOMETHASONE DIPROPIONATE
|
|
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D01AC20 | Combinations | D Dermatologicals → D01 Antifungals for dermatological use → D01A Antifungals for topical use → D01AC Imidazole and triazole derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: SG | Health Sciences Authority | Identifier(s): 03941P |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
